Nabila Elzind, MD
Neurology · Lawton, OKNPI 1003849035
Payments from drug & device makers
Across 992 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- EMD Serono, Inc.$2K
- Biogen$1K
- Novartis$1K
- Teva Pharmaceuticals USA, Inc.$803
- Eisai Inc.$680
- plus $8K from 47 others
What the payments were for
- Speaking & faculty fees$330%
- Food & beverage$16,10398%
- Education$2492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL DBS$146
How this compares
$16,385 in reported general payments places this provider in the 70th percentile of 152 neurology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 51 | $400,936 |
| Austedo XrDeutetrabenazine | 27 | $291,983 |
| VumerityDiroximel Fumarate | 25 | $230,163 |
| FinteplaFenfluramine Hcl | 11 | $208,741 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 12 | $146,372 |
| Kesimpta PenOfatumumab | 15 | $133,000 |
| Nurtec OdtRimegepant Sulfate | 76 | $114,631 |
| Teriflunomide | 13 | $77,674 |
| NuplazidPimavanserin Tartrate | 13 | $70,540 |
| Aimovig AutoinjectorErenumab-Aooe | 70 | $59,528 |
| UbrelvyUbrogepant | 36 | $50,361 |
| AptiomEslicarbazepine Acetate | 35 | $48,372 |
| BriviactBrivaracetam | 44 | $47,193 |
| QuliptaAtogepant | 38 | $47,142 |
| NayzilamMidazolam | 18 | $42,494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $505 | $425,06179 claims |
| UCB, Inc.Fintepla, Briviact, Nayzilam | $2,118 | $298,42873 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $803 | $291,98327 claims |
| BiogenVumerity | $1,433 | $230,16325 claims |
| PfizerNurtec Odt, Eliquis, Premarin | $176 | $129,052109 claims |
| AbbVieUbrelvy, Qulipta, Linzess | $154 | $104,43387 claims |
| Acadia Pharmaceuticals IncNuplazid | $565 | $70,54013 claims |
| Lilly USA, LLCMounjaro | $105 | $42,38939 claims |
| MDD US Operations, LLCGocovri | $219 | $39,21712 claims |
| Amneal Pharmaceuticals LLCRytary | $158 | $30,89140 claims |
| Eisai Inc.Fycompa | $680 | $28,39018 claims |
| SK Life Science, Inc.Xcopri | $435 | $15,73413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 152 neurology providers in Oklahoma.
Other neurology in Lawton
- Saurabh LalanLawton$15K
- Luis ReinaLawton$6K
- Gabriel PardoOklahoma City$10.3M
- Michael KarathanosTulsa$4.4M
- Cherian KarunapuzhaOklahoma City$4.1M
- Aimee BorazanciTulsa$1.9M
- Jaclyn DuvallTulsa$1.4M
- James BattisteOklahoma City$1.1M
- Tania ReynaTulsa$950K
- Mariana VargaOklahoma City$670K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.